Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma
Authors:
- Sanjay SharmaSSSanjay Sharma
- Michael H NealeMNMichael H Neale
- Federica Di NicolantonioFNFederica Di Nicolantonio
- Louise A KnightLKLouise A Knight
- Pauline A WhitehousePWPauline A Whitehouse
- Stuart J MercerSMStuart J Mercer
- Bernard R HigginsBHBernard R Higgins
- Alan LamontALAlan Lamont
- Richard OsborneRORichard Osborne
- Andrew C HindleyAHAndrew C Hindley
- Christian M KurbacherCKChristian M Kurbacher
- Ian A CreeICIan A Cree
Open Access
- 3 July 2003
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 3 (1) , 19
Abstract
We wished to evaluate the clinical response following ATP-Tumor Chemosensitivity Assay (ATP-TCA) directed salvage chemotherapy in a series of UK patients with advanced ovarian cancer. The results are compared with that of a similar assay used in a different country in terms of evaluability and clinical endpoints. From November 1998 to November 2001, 46 patients with pre-treated, advanced ovarian cancer were given a total of 56 courses of chemotherapy based on in-vitro ATP-TCA responses obtained from fresh tumor samples or ascites. Forty-four patients were evaluable for results. Of these, 18 patients had clinically platinum resistant disease (relapse < 6 months after first course of chemotherapy). There was evidence of cisplatin resistance in 31 patients from their first ATP-TCA. Response to treatment was assessed by radiology, clinical assessment and tumor marker level (CA 125). The overall response rate was 59% (33/56) per course of chemotherapy, including 12 complete responses, 21 partial responses, 6 with stable disease, and 15 with progressive disease. Two patients were not evaluable for response having received just one cycle of chemotherapy: if these were excluded the response rate is 61%. Fifteen patients are still alive. Median progression free survival (PFS) was 6.6 months per course of chemotherapy; median overall survival (OAS) for each patient following the start of TCA-directed therapy was 10.4 months (95% confidence interval 7.9–12.8 months). The results show similar response rates to previous studies using ATP-TCA directed therapy in recurrent ovarian cancer. The assay shows high evaluability and this study adds weight to the reproducibility of results from different centres.Keywords
This publication has 44 references indexed in Scilit:
- Treatment of advanced ovarian cancerEuropean Journal of Cancer, 2001
- The Costs and Efficacy of Liposomal Doxorubicin in Platinum-Refractory Ovarian Cancer in Heavily Pretreated PatientsGynecologic Oncology, 2001
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI: Journal of the National Cancer Institute, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Continued Chemosensitivity to Cisplatin/Carboplatin in Ovarian Carcinoma Despite Treatment with Multiple Prior Platinum-Based RegimensGynecologic Oncology, 1997
- Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivityAnti-Cancer Drugs, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Justification for Evaluating New Anticancer Drugs in Selected Untreated Patients With Extensive-Stage Small-Cell Lung Cancer: An Eastern Cooperative Oncology Group Randomized StudyJNCI: Journal of the National Cancer Institute, 1992
- A southwest oncology group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancerCancer, 1991
- Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compoundsGynecologic Oncology, 1990